Manuscripts
Showing 1543 manuscripts.
Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.
Citation
Susan Swindells, Hongyu Jiang, Lisa Mukherjee, Mark A. Winters, Ronald J. Bosch, David Katzenstein. Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.. HIV Clinical Trials. 2011. 12: 79-88. PMID: 21498151Year
2011
Journal
HIV Clinical Trials
Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection
Citation
Elizabeth Connick, Ronald J. Bosch, Evgenia Aga, Rick Schlichtemeier, Lisa M. Demeter, Paul Volberding. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. Journal of Acquired Immune Deficiency Syndromes. 2011. 58: 1-8. PMID: 21637110Year
2011
Journal
Journal of Acquired Immune Deficiency Syndromes
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study
Citation
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clinical Trials. 2011. 12: 201-14. PMID: 22044856Year
2011
Journal
HIV Clinical Trials
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study
Citation
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. Journal of Acquired Immune Deficiency Syndromes. 2011. 58: 253-60. PMID: 21857357Year
2011
Journal
Journal of Acquired Immune Deficiency Syndromes
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings
Citation
Kevin R. Robertson. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. Journal of Neurovirology. 2011. 17: 438-47. PMID: 21786076Year
2011
Journal
Journal of Neurovirology
Short Communication: Transplacental Nucleoside Analogue Exposure and Mitochondrial Parameters in HIV-Uninfected Children
Citation
Susan Brogly, Salvatore Dimauro, Russell B. Van Dyke, Paige L. Williams, Ali Naini, Daniel E. Libutti, Julia Choi, Michelle Chung, Mariana Gerschenson. Short Communication: Transplacental Nucleoside Analogue Exposure and Mitochondrial Parameters in HIV-Uninfected Children. AIDS. 2011. 27: 777-83. PMID: 21142587Year
2011
Journal
AIDS
Sexual health, HIV risk, and retention in an adolescent HIV vaccine trial preparatory cohort
Citation
Heather Jaspan, L. Myer, A. J. Flisher, Keren Middelkoop, D. Mark, Catherine Mathews, Linda-Gail Bekker. Sexual health, HIV risk, and retention in an adolescent HIV vaccine trial preparatory cohort. Journal of Adolescent Health. 2011. 49: 42-46. PMID: 21700155Year
2011
Journal
Journal of Adolescent Health
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS clinical trials group study A5142
Citation
Todd Hulgan, Richard H. Haubrich, Sharon A. Riddler, Pablo Tebas, Marylyn D. Ritchie, Grace McComsey, David W. Haas, Jeffrey A. Canter. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS clinical trials group study A5142. AIDS. 2011. 25: 37-47. PMID: 20871389Year
2011
Journal
AIDS
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
Citation
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011. 25: 2269-2278. PMID: 21941167Year
2011
Journal
AIDS
Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
Citation
Kit Simpson, Rukmini Rajagopalan, Birgitta Dietz, Kevin W. Garren, Sharon A. Riddler, Richard H. Haubrich. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Effectiveness and Resource Allocation. 2011. 9: 5. PMID: 21548986Year
2011
Journal
Cost Effectiveness and Resource Allocation